Birmingham vasculitis activity score (BVAS) dim system necrotizinig vasculitis

QJM

Volumn 87, Issue 11, 1994, Pages 671-678

  Luqmani, R A ^a   Bacon, P A ^a   Moots, R J ^a   Janssen, B A ^a   Pall, A ^a,b   Emery, P ^a   Savage, C ^a   Adu, D ^a  

^a Departments of Rheumatology ^*  (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MORBIDITY; NECROTIZING ARTERITIS; OBSERVER VARIATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REPRODUCIBILITY; SCORING SYSTEM; SEROLOGY; SYMPTOM;

ACUTE DISEASE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDIES; ENGLAND; EVALUATION STUDIES; HUMAN; OBSERVER VARIATION; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VASCULITIS;

EID: 0028150660     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/oxfordjournals.qjmed.a068882     Document Type: Article

References (15)

1. Adu D, Luqmani RA, Bacon PA. Polyarteritis, Wegener’s granulomatosis and Churg-Strauss syndrome. In: Maddison PJ, Isenberg D, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. Oxford, Oxford University Press, 1993:846-59.
2. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85.
3. Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. Ql Med 1993; 86:779-89.
4. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985; i:425-9.
5. Cohen Tervaert JW, Huitema MG, Hene RJ, et al. Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titres. Lancet 1990 336:709-11.
6. Nolle B, Specks V, Ludeman J, Rohrbach MS, De Remee RA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener’s granulomatosis. Ann Intern Med 1989; 111:28-40.
7. Olsen TL, Whiting O’Keefe QE, Hellmann DB. Validity and precision of a vasculitis activity index (VAI). Arthritis Rheum 1992; 35:S164.
8. Kallenberg CGM, Cohen Tervaert JW, Stegeman CA. Criteria for disease activity in Wegener’s granulomatosis: a requirement for longitudinal clinical studies. APMIS Suppl. 1990; 19:37-9.
9. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-10.
10. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-98.
11. Luqmani RA, Pall A, Adu D, Moots RJ, Richards N, Howie AJ, Michael J, Emery P, Bacon PA. Controlled trial of pulse vs. continuous cyclophosphamide and prednisolone in the treatment of systemic vasculitis. Arthritis Rheum 1993; 36:S96.
12. Esdaile JM, Abrahamowicz M, MacKenzie T, Hayslett JP, Kashgarian M. The time dependence of long-term prediction in lupus nephritis. Arthritis Rheum 1994; 37:359-68.
13. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DPM, Viner N, Zoma A. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86:447-58.
14. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32:1107-18.
15. Liang MH, Fortin PR, Isenberg DA, Snaith ML. Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int 1991; 11:133-6.